Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Waning, Boosting and a Path to Endemicity for SARS-CoV-2

View ORCID ProfileMatt J. Keeling, Amy Thomas, View ORCID ProfileEdward M. Hill, View ORCID ProfileRobin N. Thompson, View ORCID ProfileLouise Dyson, Michael J. Tildesley, View ORCID ProfileSam Moore
doi: https://doi.org/10.1101/2021.11.05.21265977
Matt J. Keeling
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matt J. Keeling
  • For correspondence: m.j.keeling@warwick.ac.uk
Amy Thomas
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
3Bristol Veterinary School, University of Bristol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward M. Hill
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward M. Hill
Robin N. Thompson
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin N. Thompson
Louise Dyson
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louise Dyson
Michael J. Tildesley
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
2Joint University Pandemic Epidemiology Research (JUNIPER) Consortium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Moore
1Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sam Moore
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In many countries, an extensive vaccination programme has substantially reduced the public-health impact of SARS-CoV-2, limiting the number of hospital admissions and deaths compared to an unmitigated epidemic. Ensuring a low-risk transition from the current situation to one in which SARS-CoV-2 is endemic requires maintenance of high levels of population immunity. The observed waning of vaccine efficacy over time suggests that booster doses may be required to maintain population immunity especially in the most vulnerable groups. Here, using data and models for England, we consider the dynamics of COVID-19 over a two-year time-frame, and the role that booster vaccinations can play in mitigating the worst effects. We find that boosters are necessary to suppress the imminent wave of infections that would be generated by waning vaccine efficacy. Projecting further into the future, the optimal deployment of boosters is highly sensitive to their long-term action. If protection from boosters wanes slowly (akin to protection following infection) then a single booster dose to the over 50s may be all that is needed over the next two-years. However, if protection wanes more rapidly (akin to protection following second dose vaccination) then annual or even biannual boosters are required to limit subsequent epidemic peaks an reduce the pressure on public health services.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MJK and SM were supported by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. MJK, RNT, LD and MJT were supported by the Engineering and Physical Sciences Research Council through the MathSys CDT [grant number EP/S022244/1]. MJK, EMH and MJT were supported by the Biotechnology and Biological Sciences Research Council [grant number: BB/S01750X/1]. MJK, AT, LD and MJT were supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. RNT was supported by UKRI through the Rapid Assistance in Modelling the Pandemic continuity grant [grant number: EP/V053507/1]. AT was supported by the Wellcome Trust [217509/Z/19/Z] and CoMMinS study [MR/V028545/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Updated error in the author list.

Data Availability

The ethics of the use of these data for these purposes was agreed by the UK Health Security Agency with the Governments SPI-M(O) / SAGE committees.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Waning, Boosting and a Path to Endemicity for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Waning, Boosting and a Path to Endemicity for SARS-CoV-2
Matt J. Keeling, Amy Thomas, Edward M. Hill, Robin N. Thompson, Louise Dyson, Michael J. Tildesley, Sam Moore
medRxiv 2021.11.05.21265977; doi: https://doi.org/10.1101/2021.11.05.21265977
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Waning, Boosting and a Path to Endemicity for SARS-CoV-2
Matt J. Keeling, Amy Thomas, Edward M. Hill, Robin N. Thompson, Louise Dyson, Michael J. Tildesley, Sam Moore
medRxiv 2021.11.05.21265977; doi: https://doi.org/10.1101/2021.11.05.21265977

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (423)
  • Anesthesia (97)
  • Cardiovascular Medicine (902)
  • Dentistry and Oral Medicine (172)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (408)
  • Epidemiology (8810)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1871)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1294)
  • Health Policy (644)
  • Health Systems and Quality Improvement (495)
  • Hematology (207)
  • HIV/AIDS (397)
  • Infectious Diseases (except HIV/AIDS) (10593)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1770)
  • Nursing (105)
  • Nutrition (267)
  • Obstetrics and Gynecology (344)
  • Occupational and Environmental Health (461)
  • Oncology (968)
  • Ophthalmology (285)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (560)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1847)
  • Public and Global Health (3998)
  • Radiology and Imaging (657)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (538)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (167)
  • Surgery (199)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)